GLPwatch
Rybelsus for Cardiovascular risk reduction
semaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCRybelsus (semaglutide) is not FDA-approved for reducing cardiovascular risk. Research includes studies on its efficacy, safety, and cardiovascular outcomes, such as the SELECT trial, but these findings do not establish FDA approval for this use.
AI summary of the sources below.
| Drug | Rybelsus (semaglutide) |
|---|---|
| Condition | Cardiovascular risk reduction |
| Approval status | Investigational / off-label |
| Research papers | 50 |
Rybelsus is not FDA-approved for cardiovascular risk reduction; the research below reflects investigational or off-label study only.
Research on semaglutide for cardiovascular risk reduction (50)
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- The Discovery and Development of Liraglutide and Semaglutide.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
- Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
- Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
- Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
- Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
- Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
- Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
- Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
- Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics.
- Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
- Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
- Semaglutide: First Global Approval.